SecProbe.io

CORRESP
 1
 filename1.htm

 CORRESP

 Adicet Bio, Inc. 131 Dartmouth Street, Floor 3 Boston, Massachusetts 02116

 March 12, 2025

 Via EDGAR Transmission

 United States Securities and Exchange Commission
 Division of Corporation Finance
 Office of Life Sciences
 100 F Street, N.E.
 Washington, D.C. 20549

 Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 6, 2025 (File No. 333-285609), as amended
 Ladies and Gentlemen:
 Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Adicet Bio, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “ Registration Statement ”) be accelerated to March 14, 2025, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
 Once the Registration Statement is effective, please orally confirm the event with Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. If you have any questions regarding this request, please contact Gabriela Morales-Rivera.

 Sincerely,
 Adicet Bio, Inc.

 /s/ Chen Schor
 Chen Schor President and Chief Executive Officer

 cc: Nick Harvey, Chief Financial Officer, Adicet Bio, Inc.
 Danielle Lauzon, Esq., Goodwin Procter LLP
 Gabriela Morales-Rivera, Esq., Goodwin Procter LLP

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 11, 2025

Chen Schor
Chief Executive Officer
Adicet Bio, Inc.
131 Dartmouth Street, 3rd Floor
Boston, MA 02116

 Re: Adicet Bio, Inc.
 Registration Statement on Form S-3
 Filed March 6, 2025
 File No. 333-285609
Dear Chen Schor:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gabriela Morales-Rivera, Esq.
</TEXT>
</DOCUMENT>